TY - JOUR
T1 - Comparative Gastrointestinal Blood Loss Associated with Placebo, Aspirin, and Nabumetone as Assessed by Radiochromium (51Cr)
AU - Lussier, André
AU - Davis, Alan
AU - Lussier, Yves
AU - LeBel, Etienne
PY - 1989/3
Y1 - 1989/3
N2 - Nabumetone differs from most other nonsteroidal anti‐inflammatory drugs. It is presented to the gut as a nonacidic prodrug, and is metabolized to its active form after absorption. Studies in animals and humans suggest it is less irritating to the gastrointestinal mucosa. This study compared the gastrointestinal microbleeding induced by nabumetone to aspirin (acetylsalicylic acid, ASA), and placebo in a double blind parallel study using chromium 51Cr labelled red cells to quantitate fecal blood loss (FBL) in healthy volunteers. Thirty subjects were randomized to treatment with nabumetone (2000 mg), ASA (3.6 g) or placebo for 21 days following a 7 day placebo period. Six subjects served as untreated controls. FBL in nabumetone treated subjects was not significantly different to placebo or untreated subjects. In contrast, ASA‐treated subjects exhibited significantly increased FBL than the other 3 groups (P < .0001). 1989 American College of Clinical Pharmacology
AB - Nabumetone differs from most other nonsteroidal anti‐inflammatory drugs. It is presented to the gut as a nonacidic prodrug, and is metabolized to its active form after absorption. Studies in animals and humans suggest it is less irritating to the gastrointestinal mucosa. This study compared the gastrointestinal microbleeding induced by nabumetone to aspirin (acetylsalicylic acid, ASA), and placebo in a double blind parallel study using chromium 51Cr labelled red cells to quantitate fecal blood loss (FBL) in healthy volunteers. Thirty subjects were randomized to treatment with nabumetone (2000 mg), ASA (3.6 g) or placebo for 21 days following a 7 day placebo period. Six subjects served as untreated controls. FBL in nabumetone treated subjects was not significantly different to placebo or untreated subjects. In contrast, ASA‐treated subjects exhibited significantly increased FBL than the other 3 groups (P < .0001). 1989 American College of Clinical Pharmacology
UR - http://www.scopus.com/inward/record.url?scp=0024596762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024596762&partnerID=8YFLogxK
U2 - 10.1002/j.1552-4604.1989.tb03317.x
DO - 10.1002/j.1552-4604.1989.tb03317.x
M3 - Article
C2 - 2786009
AN - SCOPUS:0024596762
SN - 0091-2700
VL - 29
SP - 225
EP - 229
JO - The Journal of Clinical Pharmacology
JF - The Journal of Clinical Pharmacology
IS - 3
ER -